stockrow
Friday 6 November 2026
Export MIRM’s income statement to Excel — free account
Mirum Pharmaceuticals, Inc.
MIRM Healthcare Biotechnology
Mirum Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $521.3 million, up 54.7% from fiscal 2024.
- Revenue
- +39.6%
- EPS
- −1,136.8%
- Free cash flow
- −114.2%
- Total debt
- +136.4%
Quarter to September 2026, against a year earlier
93.82
0.28
+0.30%
Follow MIRM
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Sep ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | 19 | 77 | 186 | 337 | 521 | 671 | +128.5% | 698 | 820 | 1,068 | +27.0% | |
| Gross margin, % | — | — | — | 0.00 | 0.00 | 90.06 | 83.94 | 74.76 | 75.77 | 80.77 | 81.72 | +80.8 pt | ||||||
| EBT | — | — | (17) | (53) | (103) | (84) | (142) | (162) | (87) | (21) | (900) | +3.1% | ||||||
| EBT margin, % | — | — | 0.00 | 0.00 | 0.00 | (438.66) | (184.36) | (87.15) | (25.80) | (4.11) | (134.23) | (4.1) pt | ||||||
| Net income | — | 0 | (17) | (53) | (103) | (84) | (136) | (163) | (88) | (23) | (904) | n/m | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | 0.00 | 0.00 | 0.00 | 0.63 | 2.28 | 4.56 | 7.09 | 10.39 | 10.24 | n/m | |||||
| Earnings | — | — | (19.30) | (4.58) | (4.09) | (2.77) | (4.01) | (3.94) | (1.85) | (0.47) | (15.22) | (41.2%) | ||||||
| Cash flow | — | — | (0.41) | (3.43) | (3.53) | (4.38) | (3.55) | (1.74) | 0.22 | 1.11 | (4.14) | n/m | ||||||
| Capex | — | — | (8.34) | (0.02) | (0.01) | (0.63) | (0.01) | (0.49) | (0.44) | (0.02) | (0.57) | (58.1%) | ||||||
| Free cash flow | — | — | (8.76) | (3.45) | (3.54) | (5.01) | (3.56) | (2.23) | (0.22) | 1.09 | (4.71) | n/m | ||||||
| Book value | — | — | (19.26) | 11.35 | 6.82 | 3.96 | 4.20 | 6.08 | 4.75 | 6.27 | (0.83) | n/m | ||||||
| Shares, m | — | — | 1 | 11 | 25 | 30 | 34 | 41 | 48 | 50 | 59 | +77.6% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 | |||||
| P/S | — | — | — | — | — | 0.00 | 8.47 | 6.59 | 5.83 | 7.61 | 9.17 | 5.7 | ||||||
| P/B | — | — | — | — | — | 4.02 | 4.59 | 4.94 | 8.71 | 12.60 | 0.00 | 7.0 | ||||||
| EV/Sales | — | — | — | — | — | 0.00 | 8.33 | 6.69 | 5.92 | 7.47 | 9.70 | 5.7 | ||||||
| EV/FCF | — | — | — | — | — | (3.46) | (5.33) | (13.70) | (127.19) | 130.27 | (21.06) | (3.9) | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | 0 | (39) | (89) | (133) | (120) | (71) | 10 | 56 | (271) | n/m | |||||
| Capex | — | — | (7) | 0 | 0 | (19) | 0 | (20) | (21) | (1) | (38) | (25.5%) | ||||||
| Free cash flow | — | — | (8) | (40) | (89) | (152) | (120) | (91) | (11) | 55 | (309) | n/m | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | 50 | 106 | 218 | 124 | 125 | 300 | 266 | 344 | 304 | +31.9% | |||||
| Net debt | — | — | (52) | (113) | (182) | (25) | (10) | 20 | 28 | (74) | 358 | +5.1% | ||||||
| Shareholders’ equity | — | — | (17) | 130 | 172 | 120 | 142 | 249 | 226 | 315 | (54) | n/m | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | (66.76) | (52.90) | (53.29) | (31.37) | (41.90) | (32.70) | (13.35) | (3.09) | (99.78) | +63.7 pt | |||||
| ROIC | — | — | 0.00 | (201.97) | 0.00 | (113.49) | (62.17) | (25.38) | (21.61) | (5.74) | (184.65) | (5.7) pt | ||||||
| ROE | — | — | (30.69) | (92.98) | (68.29) | (57.47) | (103.46) | (83.65) | (37.08) | (8.65) | (760.01) | +22.0 pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | 20 | 33 | 68 | 137 | 196 | 264 | 322 | 372 | — | +51.8% | |||||
| Revenue/emp, $m | — | — | 0.00 | 0.00 | 0.00 | 0.14 | 0.39 | 0.71 | 1.05 | 1.40 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2025 · latest quarter Sep 2026 · fundamentals updated 5 Nov 2026
Mirum Pharmaceuticals, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| IONS Ionis Pharmaceuticals, Inc. | $6.5B | — (loss-making) | — (loss-making) | −40.73% (below 0%: shrinking) | n/m | +299.29% (above 0%: growing) | 98.98% | (38.18%) | Compare |
| ORKA Oruka Therapeutics, Inc. | $6.4B | — (loss-making) | — | — | n/m | −43.00% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| MIRM Mirum Pharmaceuticals, Inc. | $6.1B | — (loss-making) | — (loss-making) | +39.63% (above 0%: growing) | n/m | −114.22% (below 0%: shrinking) | 81.06% | (32.17%) | |
| LGND Ligand Pharmaceuticals Incorporated | $6.0B | 116× | 88.3× | −31.80% (below 0%: shrinking) | n/m | −268.45% (below 0%: shrinking) | 96.63% | (20.01%) | Compare |
| IMVT Immunovant, Inc. | $5.9B | — (loss-making) | — | — | n/m | −5.96% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| BLTE Belite Bio, Inc. Sponsored ADR | $5.8B | — (loss-making) | — | — | n/m | +64.67% (above 0%: growing) | — | 0.00% | Compare |
| CGON CG Oncology, Inc. | $5.7B | — (loss-making) | — (loss-making) | +2,125.00% (above 0%: growing) | n/m | −67.60% (below 0%: shrinking) | (239.24%) | (7,467.68%) | Compare |
| KOD Kodiak Sciences Inc. | $5.7B | — (loss-making) | — | — | n/m | −33.86% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| PTCT PTC Therapeutics, Inc. | $5.5B | — (loss-making) | 42.2× | +69.57% (above 0%: growing) | n/m | +90.28% (above 0%: growing) | 93.39% | 7.02% | Compare |
| Median of peers | $5.8B | — | — | +18.89% | — | −19.91% | 0.00% | 0.00% |
Pay and ownership Proxy statement filed 23 April 2026
Chief executive’s pay
| Year | Total pay | Actually paid | $100 invested |
|---|---|---|---|
| 2025 | 10.44m | 29.65m | 495.24 |
| 2024 | 6.60m | 13.02m | 259.25 |
| 2023 | 6.45m | 9.43m | 185.08 |
| 2022 | 4.40m | 6.50m | 122.26 |
Ownership
Directors and executive officers, together
8.32%
Janus Henderson Group plc
10.05%
Patrick Heron
6.80%
Frazier Life Sciences IX, L.P.
5.91%
BlackRock, Inc.
5.58%
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards
at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s
shares at the start of the earliest year shown was worth at each year’s end.
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement
Mirum Pharmaceuticals, Inc. (MIRM) Latest News
4 Nov
3 Nov
27 Oct
12 Oct
29 Sep
28 Sep
25 Sep
MIRM metrics, ten years each
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score